- PolyPid Ltd. (PYPD, Financial) to host a conference call and webcast on June 9, 2025, at 8:30 AM ET.
- Discussion to focus on topline results from the SHIELD II Phase 3 trial evaluating D-PLEX100.
- D-PLEX100 targets prevention of surgical site infections in abdominal colorectal surgery patients.
PolyPid Ltd. (PYPD), a late-stage biopharma company, has scheduled a conference call and webcast for Monday, June 9, 2025, at 8:30 AM Eastern Time. The call aims to present the topline results from the SHIELD II Phase 3 trial, which evaluates the efficacy of D-PLEX100 in preventing surgical site infections in patients undergoing abdominal colorectal surgery.
This event will provide insights into the trial outcomes and the potential impact of D-PLEX100 on enhancing surgical outcomes. Participants are encouraged to register at least five minutes before the start time to ensure connectivity. The conference call can be accessed via the provided registration link, and a webcast will also be available for broader accessibility.
PolyPid's SHIELD II Phase 3 trial is a pivotal study in their commitment to developing innovative solutions for surgical site infection prevention. The company's proprietary PLEX (Polymer-Lipid Encapsulation matrix) technology supports this initiative by enabling controlled and prolonged drug release, which is critical for addressing this medical challenge.
